Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Anusha Thadi1, Lauren Lewis1, Eve Goldstein1
1Division of Surgical Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, U.S.A.
Background/Aim:
Anticancer peptide PNC-27 binds to HDM-2 protein on cancer cell membranes inducing the formation of cytotoxic transmembrane pores. Herein, we investigated HDM-2 membrane expression and the effect of PNC-27 treatment on human non-stem cell acute myelogenous leukemia cell lines: U937, acute monocytic leukemia; OCI-AML3, acute myelomonocytic leukemia and HL60, acute promyelocytic leukemia.
Materials And Methods:
We measured cell surface membrane expression of HDM-2 using flow cytometry. Cell viability was assessed using MTT assay while direct cytotoxicity was measured by lactate dehydrogenase (LDH) release and induction of apoptotic markers annexin V and caspase-3.
Results:
HDM-2 is expressed at high levels in membranes of U937, OCI-AML3 and HL-60 cells. PNC-27 can bind to membrane HDM-2 to induce cell necrosis and LDH release within 4 h.
Conclusion:
Targeting membrane HDM-2 can be a potential strategy to treat leukemia. PNC-27 targeting membrane HDM-2 demonstrated significant anti-leukemia activity in a variety of leukemic cell lines.
Insights
Anticancer peptide PNC-27 effectively targets HDM-2 on leukemia cells, inducing cell death. This study shows targeting membrane HDM-2 is a promising strategy for treating acute myelogenous leukemia.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The anticancer peptide PNC-27 targets the HDM-2 protein found on cancer cell membranes.
- HDM-2's role in inducing cytotoxic transmembrane pores is a key mechanism of action.
- This study focuses on human non-stem cell acute myelogenous leukemia (AML) cell lines.
Purpose of the Study:
- Investigate HDM-2 membrane expression in specific AML cell lines (U937, OCI-AML3, HL60).
- Evaluate the therapeutic effect of PNC-27 treatment on these leukemia cell lines.
- Determine if targeting membrane HDM-2 is a viable strategy for leukemia treatment.
Main Methods:
- Flow cytometry was used to measure cell surface membrane expression of HDM-2.
- Cell viability was assessed using the MTT assay.
- Cytotoxicity was quantified by lactate dehydrogenase (LDH) release and analysis of apoptotic markers (annexin V, caspase-3).
Main Results:
- High levels of HDM-2 expression were observed on the membranes of U937, OCI-AML3, and HL-60 cells.
- PNC-27 demonstrated binding to membrane HDM-2.
- PNC-27 induced rapid cell necrosis and LDH release within 4 hours.
Conclusions:
- Targeting membrane HDM-2 presents a potential therapeutic strategy for leukemia.
- PNC-27 exhibits significant anti-leukemia activity by targeting membrane HDM-2 in various leukemic cell lines.
More Related Videos
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
